Urea substituted imidazoquinoline ethers
    5.
    发明申请
    Urea substituted imidazoquinoline ethers 失效
    脲取代的咪唑并喹啉醚

    公开(公告)号:US20050215581A1

    公开(公告)日:2005-09-29

    申请号:US11132546

    申请日:2005-05-19

    CPC分类号: C07D471/04 A61K31/4745

    摘要: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and urea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

    摘要翻译: 在1位含有醚和脲官能团的咪唑并喹啉和四氢咪唑并喹啉化合物可用作免疫应答调节剂。 本发明的化合物和组合物可以诱导各种细胞因子的生物合成,并且可用于治疗各种病症,包括病毒性疾病和肿瘤性疾病。

    Multicyclic erythromycin derivatives
    8.
    发明授权
    Multicyclic erythromycin derivatives 失效
    多环红霉素衍生物

    公开(公告)号:US5922683A

    公开(公告)日:1999-07-13

    申请号:US87035

    申请日:1998-05-29

    IPC分类号: C07H17/08 A61K31/70

    CPC分类号: C07H17/08

    摘要: Novel multicyclic erythromycin compounds and pharmaceutically acceptable salts and esters thereof having antibacterial activity having a formula ##STR1## pharmaceutical compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier, as well as a method for treating bacterial infections by administering to a mammal a pharmaceutical composition containing a therapeutically-effective amount of a compound of formula (I).

    摘要翻译: 具有抗菌活性的具有抗菌活性的新型多环红霉素化合物及其药学上可接受的盐和酯,其具有式药物组合物,其包含治疗有效量的本发明化合物与药学上可接受的载体的组合,以及通过给予 哺乳动物含有治疗有效量的式(I)化合物的药物组合物。

    Substituted chiral fused [1,2] imidazo [4,5-C] ring compounds and methods
    10.
    发明申请
    Substituted chiral fused [1,2] imidazo [4,5-C] ring compounds and methods 失效
    取代的手性稠合[1,2]咪唑并[4,5-C]环化合物和方法

    公开(公告)号:US20080070907A1

    公开(公告)日:2008-03-20

    申请号:US11827648

    申请日:2007-07-12

    CPC分类号: C07D498/14

    摘要: Substituted fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines, and imidazo[4,5-c]pyridines) with a —CH(—R2)— group in the fused ring at the 2-position of the imidazo ring and a —CH(—R1)— group in the fused ring at the 1-position of the imidazo ring, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

    摘要翻译: 取代的稠合[1,2]咪唑并[4,5-c]环化合物(例如咪唑并[4,5-c]喹啉,6,7,8,9-四氢咪唑并[4,5-c]喹啉,咪唑并[ 4,5-c]萘啶,6,7,8,9-四氢咪唑并[4,5-c]萘啶和咪唑并[4,5-c]吡啶),其中-CH(-R 2) 在咪唑环的1位上的稠合环中的咪唑环的2-位的稠合环中的-CH 2 - (CH 2 - ) - 基团和-CH(-R 1) 公开了含有化合物的药物组合物,制备该化合物的方法,以及这些化合物用作免疫调节剂的方法,用于诱导动物中的细胞因子生物合成和治疗包括病毒和肿瘤疾病在内的疾病。